MARKET

VRCDF

VRCDF

Verici Dx
OTCPK
--
NaN%
Closed 09:30 05/16 EDT
OPEN
--
PREV CLOSE
--
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
--
52 WEEK LOW
--
MARKET CAP
--
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
1D
No Data
About VRCDF
Verici Dx plc is an immuno-diagnostics development company. The Company develops a suite of tests forming a kidney transplant platform for personalized patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The principal activity is the development of prognostic and diagnostic tests for kidney transplant patients. The Company's kidney transplant assays use sequencing that defines a personalized risk-profile of each patient over the course of the transplant journey. The Company develops tests to understand how a patient is responding to organ transplants. Its products include Clarava, Tuteva and Protega. Clarava is a pre-transplant prognosis for the risk of early acute rejection (EAR). Tuteva is a post-transplant diagnostic focused upon acute cellular rejection (ACR), including subclinical rejection. Protega is a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. Its subsidiary is Verici Dx Inc.

Webull offers Verici DX PLC stock information, including OTCPK: VRCDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRCDF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VRCDF stock methods without spending real money on the virtual paper trading platform.